These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29182807)

  • 21. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
    Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
    Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Free circulating DNA as a tool for lung cancer patients management].
    Tissot C; Villar S; Olivier M; Couraud S
    Rev Pneumol Clin; 2016 Feb; 72(1):61-71. PubMed ID: 26190335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-Free DNA in Oncology: Gearing up for Clinic.
    Ulrich BC; Paweletz CP
    Ann Lab Med; 2018 Jan; 38(1):1-8. PubMed ID: 29071812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
    He J; Tan W; Ma J
    Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Blood-based Tumor Markers in Lung Cancer].
    Zhou C
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):770-80. PubMed ID: 26706955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Origin of circulating free DNA in patients with lung cancer.
    Abe T; Nakashima C; Sato A; Harada Y; Sueoka E; Kimura S; Kawaguchi A; Sueoka-Aragane N
    PLoS One; 2020; 15(7):e0235611. PubMed ID: 32634139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Biopsy - Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer.
    Raycheva GA; Ivanov HY; Grudeva-Popova ZG
    Folia Med (Plovdiv); 2021 Dec; 63(6):839-846. PubMed ID: 35851241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
    Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
    Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy approaches for pleural effusion in lung cancer patients.
    Baburaj G; Damerla RR; Udupa KS; Parida P; Munisamy M; Kolesar J; Rao M
    Mol Biol Rep; 2020 Oct; 47(10):8179-8187. PubMed ID: 33029702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient Capture and Isolation of Tumor-Related Circulating Cell-Free DNA from Cancer Patients Using Electroactive Conducting Polymer Nanowire Platforms.
    Jeon S; Lee H; Bae K; Yoon KA; Lee ES; Cho Y
    Theranostics; 2016; 6(6):828-36. PubMed ID: 27162553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy in lung cancer management.
    Irofei Zamfir MA; Buburuzan L; Hudiţă A; Gălăţeanu B; Ginghină O; Ion D; Motaş N; Ardeleanu CM; Costache M
    Rom J Morphol Embryol; 2022; 63(1):31-38. PubMed ID: 36074665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.
    Casagrande GMS; Silva MO; Reis RM; Leal LF
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
    Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].
    Dahl E; Kloten V
    Pathologe; 2015 Nov; 36(6):572-8. PubMed ID: 26395890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Breakthrough Technologies: Liquid Biopsy -Chairmen's Introductory Remarks.].
    Nakatani K; Furuta K
    Rinsho Byori; 2016 May; 64(4):392-393. PubMed ID: 29182804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.